OncoSec Medical Inc (ONCS) : Ridgeback Capital Investments added new position in OncoSec Medical Inc during the most recent quarter end. The investment management firm now holds 1,292,614 shares of OncoSec Medical Inc which is valued at $2.1 Million , the company said in a statement filed on May 13, 2016 with the SEC.OncoSec Medical Inc makes up approximately 16.68% of Ridgeback Capital Investments’s portfolio.
Other Hedge Funds, Including , Sabby Management reduced its stake in ONCS by selling 113,011 shares or 9.23% in the most recent quarter. The Hedge Fund company now holds 1,111,348 shares of ONCS which is valued at $1.8 Million. OncoSec Medical Inc makes up approx 0.62% of Sabby Management’s portfolio. Spark Investment Management sold out all of its stake in ONCS during the most recent quarter. The investment firm sold 12,830 shares of ONCS which is valued $20,656.Edmond De Rothschild Holding S.a. reduced its stake in ONCS by selling 8,000 shares or 71.11% in the most recent quarter. The Hedge Fund company now holds 3,250 shares of ONCS which is valued at $5,233.Blackrock Fund Advisors reduced its stake in ONCS by selling 2,505 shares or 6.21% in the most recent quarter. The Hedge Fund company now holds 37,848 shares of ONCS which is valued at $60,935.Janney Montgomery Scott boosted its stake in ONCS in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 12,100 shares of OncoSec Medical Inc which is valued at $19,481.
OncoSec Medical Inc opened for trading at $1.65 and hit $1.65 on the upside on Wednesday, eventually ending the session at $1.64, with a gain of 0.61% or 0.01 points. The heightened volatility saw the trading volume jump to 1,47,418 shares. Company has a market cap of $28 M.
OncoSec Medical Incorporated is a biotechnology company focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types. The Company’s technology includes property relating to its ImmunoPulse delivery technology. The Company’s ImmunoPulse is an electroporation delivery device that the Company uses in combination with its therapeutic product candidates including deoxyribonucleic acid (DNA) plasmids that encode for immunologically active agents to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. Its electroporation devices consist of an electrical pulse generator and disposable applicators. The Company’s ImmunoPulse product candidates are based on its DNA based immunotherapy technology.